Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC42BPB | Q9Y5S2 | 13/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.42 |
| ▸ | CDC42BPA | Q5VT25 | 5/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252862 | 0.79 | AR (0.41) | — | |
| SCHEMBL30751784 | 0.78 | ROCK2 (0.55) | CDC42BPBROCK1ROCK2CDC42BPAGRM1 | |
| SCHEMBL565865 | 0.78 | ROCK2 (0.55) | CDC42BPBROCK1ROCK2CDC42BPAGRM1 | |
| SCHEMBL16339823 | 0.78 | MAPT (0.40) | CDC42BPBROCK1ROCK2CDC42BPA | |
| SCHEMBL3345307 | 0.77 | ROCK2 (0.59) | CDC42BPBROCK1ROCK2CDC42BPAPARP1 | |
| SCHEMBL2490475 | 0.72 | SIRT3 (0.42) | ROCK2CHRM1 | |
| SCHEMBL2490935 | 0.71 | KDM4E (0.43) | — | |
| SCHEMBL4106691 | 0.71 | AR (0.61) | — | |
| SCHEMBL4091463 | 0.70 | AR (0.63) | — | |
| SCHEMBL30510121 | 0.69 | GSK3B (0.47) | CDC42BPBROCK1ROCK2CDC42BPAGRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856183-A1 | alfa2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2021-08-04 | — | — | EP | claimed |
| WO-2020064479-A1 | α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-02 | — | — | WO | claimed |
| EP-2364303-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | Orion Corporation (FI) | 2011-09-14 | — | — | EP | claimed |
| WO-2010058060-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2010-05-27 | — | — | WO | claimed |
| EP-2066659-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-06-10 | — | — | EP | claimed |
| WO-2008040492-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-04-10 | — | — | WO | claimed |
| EP-3856183-A1 | alfa2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020064479-A1 | α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-02 | — | — | WO | disclosed |
| WO-2014207508-A1 | PYRIDYL COMPOUND SUITABLE FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2014-12-31 | — | — | WO | disclosed |
| EP-2364303-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | Orion Corporation (FI) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010058060-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2010-05-27 | — | — | WO | disclosed |
| EP-2066659-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008040492-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-04-10 | — | — | WO | disclosed |